We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.
Dr. Reddy's (RDY) posts better-than-expected fiscal fourth-quarter results on growth in global generics revenues in North America as well as Emerging Markets.
Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.
Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter earnings release, given the absence of a marketed product.
ANI Pharmaceuticals' (ANIP) revenues in the first quarter of 2024 are likely to have been driven by increased sales of its lead product, Cortrophin Gel, as well as growth in its generics business.
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), QUALCOMM Incorporated (QCOM) and FedEx Corporation (FDX).
Kymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the current cash balance to provide a runway into the first half of 2027.
Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.
pharmaceuticals: Archive
Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses
by Zacks Equity Research
Prothena (PRTA) posts a wider-than-expected loss in the first quarter on lower revenues and higher costs.
RHHBYPositive Net Change BMYNegative Net Change NVONegative Net Change PRTAPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
by Zacks Equity Research
Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.
LGNDNegative Net Change CPRXNegative Net Change ANIPNegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down
by Zacks Equity Research
Viatris (VTRS) Q1 numbers fall short of estimates. The company adjusts the annual guidance to reflect the impact of divestitures.
LGNDNegative Net Change ANIPNegative Net Change BBIOPositive Net Change VTRSNegative Net Change
earnings medical pharmaceuticals
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.
VRTXPositive Net Change UTHRNegative Net Change LGNDNegative Net Change CRSPNegative Net Change
biotechs cell-therapy crispr earnings gene-editing gene-therapy immuno-therapy medical pharmaceuticals
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.
LGNDNegative Net Change ANIPNegative Net Change ACADNegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
LGNDNegative Net Change ANIPNegative Net Change ITCINegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports first-quarter 2024 results, wherein earnings miss but revenues beat estimates, driven by Exparel sales.
LGNDNegative Net Change PCRXPositive Net Change ANIPNegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Ionis (IONS) posts mixed first-quarter 2024 results. The company continues to focus on pipeline development.
AZNPositive Net Change NVSNegative Net Change BIIBNegative Net Change IONSNegative Net Change
pharmaceuticals
Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow
by Zacks Equity Research
Dr. Reddy's (RDY) posts better-than-expected fiscal fourth-quarter results on growth in global generics revenues in North America as well as Emerging Markets.
RDYNegative Net Change LGNDNegative Net Change ANIPNegative Net Change BBIOPositive Net Change
earnings medical pharmaceuticals
Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus
by Zacks Equity Research
Denali (DNLI) Q1 loss narrows year over year due to lower expenses despite nil revenues.
SNYNegative Net Change BIIBNegative Net Change LGNDNegative Net Change DNLINegative Net Change
biotechnology biotechs earnings pharmaceuticals
Bear of the Day: CVS Health (CVS)
by Jeremy Mullin
CVS continues to face headwinds amidst growth challenges.
CVSPositive Net Change WBAPositive Net Change
pharmaceuticals retail
Q1 Earnings Season Scorecard and Fresh Analyst Reports for Tesla, JNJ & Netflix
by Sheraz Mian
Today's Research Daily features the Q1 earnings season scorecard and updated analyst reports on Tesla (TSLA), JNJ (JNJ), Netflix (NFLX) and others.
ABTPositive Net Change JNJPositive Net Change COPNegative Net Change NFLXNegative Net Change TSLAPositive Net Change TTENegative Net Change
auto-tires-trucks consumer-discretionary pharmaceuticals
A Look at Pharma ETFs Post Q1 Earnings
by Sweta Killa
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
BMYNegative Net Change JNJPositive Net Change MRKNegative Net Change LLYNegative Net Change PJPNegative Net Change IHENegative Net Change XPHNegative Net Change PPHNegative Net Change FTXHNegative Net Change
earnings etfs pharmaceuticals
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.
LGNDNegative Net Change ANIPNegative Net Change APLSPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.
ANIPNegative Net Change ADVMNegative Net Change ARVNNegative Net Change ABSINegative Net Change
biotechnology biotechs pharmaceuticals
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter earnings release, given the absence of a marketed product.
CPRXNegative Net Change ADVMNegative Net Change ARGXNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
ANI Pharmaceuticals' (ANIP) revenues in the first quarter of 2024 are likely to have been driven by increased sales of its lead product, Cortrophin Gel, as well as growth in its generics business.
CPRXNegative Net Change ANIPNegative Net Change ADVMNegative Net Change ARGXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
by Kinjel Shah
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
TEVANegative Net Change PRGONegative Net Change ACADNegative Net Change IOVANegative Net Change VTRSNegative Net Change
biotechs pharmaceuticals
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Viatris' (VTRS) Q1 results are likely to gain from momentum in its branded and incremental revenues from new product launches.
CPRXNegative Net Change ANIPNegative Net Change ADVMNegative Net Change VTRSNegative Net Change
biotechs medical pharmaceuticals
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
by Zacks Equity Research
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
REGNNegative Net Change ALNYPositive Net Change NVSNegative Net Change RHHBYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.
REGNNegative Net Change LGNDNegative Net Change ANIPNegative Net Change RAREPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Top Analyst Reports for AstraZeneca, QUALCOMM & FedEx
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), QUALCOMM Incorporated (QCOM) and FedEx Corporation (FDX).
AZNPositive Net Change QCOMNegative Net Change HALPositive Net Change AIGNegative Net Change FDXNegative Net Change BKRPositive Net Change
computers pharmaceuticals transportation
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
by Kinjel Shah
Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.
JNJPositive Net Change PFEPositive Net Change NVONegative Net Change LLYNegative Net Change ABBVPositive Net Change
pharmaceuticals
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the current cash balance to provide a runway into the first half of 2027.
SNYNegative Net Change AMRNNegative Net Change ANIPNegative Net Change KYMRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
by Zacks Equity Research
Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.
LGNDNegative Net Change ANIPNegative Net Change BPMCNegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals